ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019

Jan 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-01-14

Reporting Person: GIVEN BRUCE D (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-14	Common Stock	M	11666	$2.62	Acquired	1110022	Direct
2019-01-14	Common Stock	M	1000	$6.20	Acquired	1111022	Direct
2019-01-14	Common Stock	S	42666	$14.40	Disposed	1068356	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-14	Stock Option (right to buy)	$2.62	M	11666	Disposed	2022-09-28	Common Stock (11666)	Direct
2019-01-14	Stock Option (right to buy)	$6.20	M	1000	Disposed	2019-09-28	Common Stock (1000)	Direct

Footnotes

F1: These shares were sold pursuant to a 10b5-1 plan adopted by the reporting person.

F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.03 to $14.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: Represents first vesting date. Option vested over four years from date of grant.